Results 121 to 130 of about 47,298 (270)

Investigating the Risk Factors for Medication Nonadherence in Myasthenia Gravis Patients: Establishing a Nomogram Model

Patient Preference and Adherence
Chaoying Liu,1– 3 Simei Ning,1 Ping Lu,1,2 Wenli Jia,1 Xiaohe Zhang,1– 3 Guoyan Qi1– 31Treatment Center of Myasthenia Gravis, Shijiazhuang People’s Hospital, Shijiazhuang, Hebei, People’s Republic of China; 2Hebei Provincial Key Laboratory of Myasthenia ...
Liu C, Ning S, Lu P, Jia W, Zhang X, Qi G   +5 more
doaj  

Technique of the transcervical-subxiphoid-videothoracoscopic maximal thymectomy

Journal of Minimal Access Surgery, 2007
Background: The aim of this study is to present the new technique of transcervical-subxiphoid-videothoracoscopic "maximal"thymectomy introduced by the authors of this study for myasthenia gravis.
Zielinski Marcin, Hauer Lukasz, Kuzdzal Jaroslaw, Sosnicki Witold, Harazda Maria, Pankowski Juliusz, Nabialek Tomasz, Szlubowski Artur   +7 more
doaj  

Myasthenia Gravis [PDF]

BMJ, 1959
openaire   +3 more sources

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori, Noemi Coppola, Elvira Ruoppo, Federica Canfora, Gabriele Mignogna, Ilaria Mormile, Antonia Fiore, Giuseppe Castaldo, Michele Davide Mignogna, Stefania Leuci   +9 more
wiley   +1 more source

Polymorphic myopathological findings in a 77‐year‐old woman with oculo‐bulbo‐facial and distal weakness

Brain Pathology, EarlyView.
Michele Tosi, Angela Puma, Elena Faedo, Gianmarco Severa, Luisa Villa, Sabrina Sacconi, Edoardo Malfatti   +6 more
wiley   +1 more source

The impact of statistical choice on variability and error in maximal respiratory mouth pressure testing

Experimental Physiology, EarlyView.
Abstract Various statistics have been used to assess repeatability and reproducibility of maximal inspiratory and expiratory mouth pressure measurements (PImax and PEmax, respectively). Few studies have examined the impact of rater experience on these values. The aims were to assess: (1) how choice of statistic impacted repeatability of PImax and PEmax;
Mitch Lomax, Josh Osofa, Nicola Armstrong, Michael Tipton, Gemma Milligan   +4 more
wiley   +1 more source

Animal models of myasthenia gravis: utility and limitations

, 2016
Renato Mantegazza, Chiara Cordiglieri, Alessandra Consonni, Fulvio Baggi Neurology IV Unit, Neuroimmunology and Neuromuscular Disorders, Foundation IRCCS Neurological Institute “Carlo Besta”, Milan, Italy Abstract: Myasthenia gravis (MG) is ...
Cordiglieri C, Consonni A, Mantegazza R, Baggi F   +3 more
core  

Factors Worsening the Course of Myasthenia: Latest Research and Insights

Neurologijos seminarai
Myasthenia (Latin: myasthenia gravis, MG) is an autoimmune disease that affects the neuromuscular junction, leading to pathological muscle fatigue. The main symptom of the disease is muscle fatigue, which becomes more pronounced after exertion and may ...
Viktorija Kutniauskaitė, Gabrielė Žilionytė, Evelina Grušauskienė   +2 more
doaj   +1 more source

Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis

Muscle &Nerve, Volume 74, Issue 2, Page 422-426, August 2026.
ABSTRACT Introduction/Aims Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six‐week cyclic regimen may be associated with a “wearing‐off” effect and disease fluctuations. We evaluated the non‐cyclic administration
Marc Abi Aoun, Diane Beauvais, Marlène Barnay, Marie‐Hélène Violleau, Stéphane Mathis, Fanny Duval, Guilhem Sole   +6 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced myasthenia gravis, myocarditis, and myositis: A case report

Clinical Case Reports
Key Clinical Message Immune checkpoint inhibitors can rarely lead to occurrence of myositis, myocarditis, and myasthenia gravis (MG). Early recognition and multidisciplinary management are crucial for optimal outcomes.
Arjun Basnet, Nava Raj Sharma, Sudarshan Gautam, Saral Lamichhane, Sajog Kansakar, Kripa Tiwari, Madalasa Pokhrel, Sehajpreet Singh   +7 more
doaj   +1 more source